Video Experimental Relacionado
Updated: Sep 9, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.0K
Un análisis de desproporcionalidad de los eventos adversos en el mundo real asociados con tirofibán de la base de
Qian Guo1, Xiang Li2, Chuanliang Zhao3
1Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Scientific reports
|September 1, 2025
Resumen
El tirofibán, un bloqueador de los receptores de la glicoproteína IIb/ IIIa, puede causar hemorragias graves y otras reacciones adversas (EA) en situaciones reales. El seguimiento de estos efectos secundarios, incluidos los raros como la DIC, es crucial después de la administración.
Área de la Ciencia:
- Farmacovigilancia de las sustancias
- Medicina cardiovascular
- Neurología
Sus antecedentes:
- El tirofibán es un antagonista de los receptores de la glicoproteína IIb/ IIIa.
- Se utiliza principalmente para el síndrome coronario agudo (SAA) y la angioplastia (ICP).
- La evidencia emergente sugiere beneficios potenciales en el tratamiento endovascular del ictus isquémico (IS).
Objetivo del estudio:
- Evaluar el perfil de eventos adversos en el mundo real de Tirofiban.
- Identificar los efectos secundarios comunes y raros asociados con el uso de Tirofiban.
- Informar las estrategias de seguimiento clínico de los pacientes que reciben Tirofiban.
Principales métodos:
- Análisis de la desproporcionalidad de los informes de eventos adversos de la FDA (2004-presente).
- Centrarse en los casos en los que Tirofiban fue el principal sospechoso.
- Análisis temporal de la aparición de AE.
Principales resultados:
- Efectos adversos conocidos confirmados: sangrado (por ejemplo, intracraneal, gastrointestinal) y trombocitopenia.
- Se han identificado casos de hemorragia menos frecuentes: hemotórax, shock hemorrágico.
- Se han detectado reacciones adversas raras pero significativas: insuficiencia respiratoria aguda, hemólisis, APTT prolongado, coagulopatía, coagulación intravascular diseminada (CID).
Conclusiones:
- Tirofiban está asociado con un espectro de hemorragias y otros efectos adversos graves.
- Las EAE raras como la DIC y la insuficiencia respiratoria aguda requieren atención.
- La mediana de aparición de AE es de 1 día, lo que requiere un seguimiento inmediato después de la administración, incluida la vigilancia de los síntomas y la evaluación de laboratorio.
Videos de Conceptos Relacionados
01:19Pharmacovigilance
983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:12Hazard Ratio
241
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
241
01:12Relative Risk
340
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
340
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
01:11Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152